An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma

Trial Profile

An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs ABC 294640 (Primary)
  • Indications Diffuse large B cell lymphoma; Kaposi's sarcoma
  • Focus Adverse reactions
  • Sponsors Apogee Biotechnology Corporation; RedHill Biopharma
  • Most Recent Events

    • 05 Dec 2017 Planned initiation date changed from 1 Apr 2015 to 1 Jul 2014.
    • 05 Dec 2017 Status changed from recruiting to withdrawn prior to enrolment.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top